[go: up one dir, main page]

AU1648092A - Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins - Google Patents

Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Info

Publication number
AU1648092A
AU1648092A AU16480/92A AU1648092A AU1648092A AU 1648092 A AU1648092 A AU 1648092A AU 16480/92 A AU16480/92 A AU 16480/92A AU 1648092 A AU1648092 A AU 1648092A AU 1648092 A AU1648092 A AU 1648092A
Authority
AU
Australia
Prior art keywords
epstein
barr virus
recombinant adenoviruses
virus proteins
defective recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16480/92A
Inventor
Susan Finerty
Andrew J Morgan
Michel Perricaudet
Thierry Ragot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Cancer Research Campaign Technology Ltd
Original Assignee
Centre National de la Recherche Scientifique CNRS
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Cancer Research Campaign Technology Ltd filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU1648092A publication Critical patent/AU1648092A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU16480/92A 1992-03-19 1992-03-19 Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins Abandoned AU1648092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1992/000256 WO1993019092A1 (en) 1992-03-19 1992-03-19 Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Publications (1)

Publication Number Publication Date
AU1648092A true AU1648092A (en) 1993-10-21

Family

ID=9425562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16480/92A Abandoned AU1648092A (en) 1992-03-19 1992-03-19 Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Country Status (2)

Country Link
AU (1) AU1648092A (en)
WO (1) WO1993019092A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024925A1 (en) * 1994-03-16 1995-09-21 The Council Of The Queensland Institute Of Medical Research Cytotoxic t-cell epitopes

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000655A1 (en) * 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
AU2194895A (en) * 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JPH10501136A (en) 1994-06-02 1998-02-03 カイロン コーポレイション Nucleic acid immunization using a virus-based infection / transfection system
GB9423663D0 (en) * 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
DE19731184C2 (en) * 1997-07-10 1999-10-07 Atotech Deutschland Gmbh Device for the analytical monitoring of a bath for electroplating treatment of substrate surfaces
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
AU762799B2 (en) * 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000971A1 (en) * 1986-08-01 1988-02-11 Commonwealth Scientific And Industrial Research Or Recombinant vaccine
EP0260012A1 (en) * 1986-09-02 1988-03-16 Merck & Co. Inc. Promoter for expression of heterologous proteins in mammalian cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024925A1 (en) * 1994-03-16 1995-09-21 The Council Of The Queensland Institute Of Medical Research Cytotoxic t-cell epitopes
WO1995024926A1 (en) * 1994-03-16 1995-09-21 The Council Of The Queensland Institute Of Medical Research Formulation for use in inducing cytotoxic t-cells

Also Published As

Publication number Publication date
WO1993019092A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
AU1648092A (en) Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
AU5283793A (en) Recombinant specific binding protein
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU1628895A (en) Recombinant virus
IL116816A0 (en) Recombinant defective adenoviruses
HK1004896B (en) Peptides
AU3119895A (en) Recombinant virus vectors
AU4514193A (en) Bone formation-inducing protein
AU3137093A (en) Fusion proteins comprising mgf and il-3
AU6428890A (en) Therapeutic peptides and proteins
AU4977796A (en) Modified lysine or arginine containing proteins and peptides
AU6299594A (en) Recombinant fowlpox virus s-fpv-043 and uses thereof
AU5320296A (en) Modified viral envelope polypeptide
AU5109796A (en) Export systems for recombinant proteins
AUPO026596A0 (en) Viral peptide
EP0747482A3 (en) Hepatitis GB virus recombinant proteins and uses thereof
AU5635896A (en) Recombinant endotoxin-neutralizing proteins
AU1435695A (en) Recombinant human thymopoietin proteins and uses therefor
AU5652396A (en) Glucose-inducible recombinant viral vector
EP0710120A4 (en) Recombinant swinepox virus
AU3509693A (en) A recombinant hepatitis C virus polypeptide
AU4271793A (en) Novel polypeptide
ZA946887B (en) Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor
AU4554493A (en) Interferon receptor binding peptides
AU688259B2 (en) Hepatitis C virus peptides